| HER-2阳性早期乳腺癌辅助治疗的研究进展 |
| |
| 引用本文： | 饶彬. HER-2阳性早期乳腺癌辅助治疗的研究进展[J]. 国际医药卫生导报, 2017, 23(6). DOI: 10.3760/cma.j.issn.1007-1245.2017.06.051 |
| |
| 作者姓名： | 饶彬 |
| |
| 作者单位： | 543002,梧州市红十字会医院普外二科 |
| |
| 摘 要： | 人表皮生长因子受体-2(HER-2)阳性乳腺癌是具有较强侵袭性、预后较差的一类肿瘤,曲妥珠单抗抗Her-2靶向的问世,改变了Her-2阳性乳腺癌的预后.除了曲妥珠单抗这个药物,一系列抗Her-2靶向治疗药物的相继用于临床研究及治疗,包括小分子酪氨酸激酶抑制剂拉帕替尼、来那替尼;抗Her-2分子异源二聚化的药物帕妥珠单抗以及曲妥珠单抗-细胞毒性的共轭药物(T-DM1).本文就是对HER-2阳性早期乳腺癌的辅助治疗进行综述评价.
|
| 关 键 词： | 人表皮生长因子受体-2 乳腺癌 曲妥珠单抗 帕妥珠单抗 拉帕替尼 |
Research progress of adjuvant therapy for HER-2 positive early breast cancer |
| |
| Rao Bin. Research progress of adjuvant therapy for HER-2 positive early breast cancer[J]. International Medicine & Health Guidance News, 2017, 23(6). DOI: 10.3760/cma.j.issn.1007-1245.2017.06.051 |
| |
| Authors: | Rao Bin |
| |
| Abstract: | Human epidermal growth factor receptor-2 (HER-2)-positive breast cancer is a kind of tumor with strong invasiveness and poor prognosis.Trastuzumab anti Her-2 targeted drugs has changed the prognosis of Her-2 positive breast cancer.In addition to the drug trastuzumab,a series of anti-Her-2 targeted drugs have been used in clinical research and treatment,including small molecule tyrosine kinase inhibitor (lapatinib and neratinib),anti-Her-2 molecular heterodimerization drug (pertuzumab),and cell toxicity of trastuzumab conjugated drug (T-DM1).This article is to review the treatment of HER-2 positive early breast cancer. |
| |
| Keywords: | Human epidermal growth factor receptor-2 Breast cancer Trastuzumab Pertuzumab Lapatinib |
| 本文献已被 万方数据 等数据库收录！ |
